For the first time during Black History Month the Vice President is a Black woman, representing the agency Black voters invoked to make political progress. (Feb. 25)
How Nischal Shetty, Siddharth Menon and Sameer Mhatre spotted an opportunity, survived a ban, and created India's largest crypto exchange, WazirX.
Remember when plug-in hybrid cars were the go-to technology for the climate-conscious driver? EU policy plans for plug-in hybrid vehicles (PHEVs), which contain an electric battery and a combustion engine, could mean the "transition" technology has a shorter lifespan than envisaged by some leading automakers.
Police fire tear gas at demonstrators after a black man was fatally shot during a traffic stop.
Daunte Wright, 20, was shot by police in Minnesota on Sunday before getting back into his car following a traffic stop, according to his family.
Defense attorney Eric Nelson has a broader strategy as he questions witnesses in Derek Chauvin's murder trial. His queries are aimed at undermining the dominant narrative of George Floyd's death, established through widely seen bystander video. (April 12)
What started as tour outfits for now rescheduled shows turned into a limited-edition line of ready-to-wear and sneakers from Maluma and Balmain.
Some people recover from COVID with no lasting symptoms. For others, coronavirus can cause physical and mental symptoms that last for weeks or even months after the infection has gone.
Remember when plug-in hybrid cars were the go-to technology for the climate-conscious driver? EU policy plans for plug-in hybrid vehicles (PHEVs), which contain an electric battery and a combustion engine, could mean the "transition" technology has a shorter lifespan than envisaged by some leading automakers.
WISeKey Increases its Semiconductor Manufacturing Capabilities to Support Exploding Demand WISeKey’s VaultIC Secure Elements and secure microcontrollers protect large volumes of IoT devices and consumer products. The current global pandemic situation has resulted in an exploding demand for these products that WISeKey is responding to by significantly investing in its supply chain transformation. Geneva, Switzerland – April 12, 2021: WISeKey International Holding Ltd. (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a leading global cybersecurity and IoT company today announced it is significantly investing in its supply chain transformation to better and faster serve its customers. The Company is simultaneously impacted by the current semiconductor shortage situation and a tremendously growing order backlog. While most industries are dramatically impacted by the current semiconductor shortage, market analysts predict the same situation will continue into 2022. According to experts, this shortage is the combination of several factors. The global consumer demand dropped during the beginning of the COVID-19 pandemic and the semiconductor industry had to significantly reduce its manufacturing capacity to mitigate consequences on profitability; however, the worldwide lockdown had an unforecastable positive effect on the high-tech products market: tons of new laptops, monitors, smartphones, routers, modems and gaming consoles have created a surge in chips across industries that low inventory and limited production capacities haven’t been able to resorb. Billions of WISeKey’s secure chips are embedded in high-tech products and goods to protect data, communication and firmware against cyberattacks. This includes routers, modems, energy smart meters, drones and medical devices, to mention a few. As a fabless company, WISeKey trust a network of subcontractors and partners to provide its most prestigious customers with the best leadtimes and service. While the Company’s book-to-bill ratio is exploding, it has to challenge its existing supply chain and find short and long term solutions to maintain and even continue to raise the bar on service quality. These solutions involve continuous negotiations with current suppliers and investments to diversify sourcing, including relocating some of the processes to minimize transportation and environmental effects. “WISeKey has been selected by global companies as their digital trust partner,” said Carlos Moreira, Founder and CEO of WISeKey. “Our VaultIC and other secure chips are massively used in many sensitive applications that require not only a unique technology expertise but also a perfect supply chain. We are again demonstrating reactivity and agility to provide our customers with the best business continuity in spite of the current chaotic semiconductor crisis.” To learn more about WISeKey’s cybersecurity propositions, visit WISeKey.com. About WISeKey WISeKey (NASDAQ: WKEY; SIX Swiss Exchange: WIHN) is a leading global cybersecurity company currently deploying large scale digital identity ecosystems for people and objects using Blockchain, AI and IoT respecting the Human as the Fulcrum of the Internet. WISeKey microprocessors secure the pervasive computing shaping today’s Internet of Everything. WISeKey IoT has an install base of over 1.5 billion microchips in virtually all IoT sectors (connected cars, smart cities, drones, agricultural sensors, anti-counterfeiting, smart lighting, servers, computers, mobile phones, crypto tokens etc.). WISeKey is uniquely positioned to be at the edge of IoT as our semiconductors produce a huge amount of Big Data that, when analyzed with Artificial Intelligence (AI), can help industrial applications to predict the failure of their equipment before it happens. Our technology is Trusted by the OISTE/WISeKey’s Swiss based cryptographic Root of Trust (“RoT”) provides secure authentication and identification, in both physical and virtual environments, for the Internet of Things, Blockchain and Artificial Intelligence. The WISeKey RoT serves as a common trust anchor to ensure the integrity of online transactions among objects and between objects and people. For more information, visit www.wisekey.com. Press and investor contacts: WISeKey International Holding Ltd Company Contact: Carlos Moreira Chairman & CEO Tel: +41 22 594 3000 info@wisekey.comWISeKey Investor Relations (US) Contact: Lena Cati The Equity Group Inc. Tel: +1 212 836-9611 lcati@equityny.com Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning WISeKey International Holding Ltd and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of WISeKey International Holding Ltd to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. WISeKey International Holding Ltd is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.This press release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities, and it does not constitute an offering prospectus within the meaning of article 652a or article 1156 of the Swiss Code of Obligations or a listing prospectus within the meaning of the listing rules of the SIX Swiss Exchange. Investors must rely on their own evaluation of WISeKey and its securities, including the merits and risks involved. Nothing contained herein is, or shall be relied on as, a promise or representation as to the future performance of WISeKey.
The decision came following an attack on the Togo team bus in Angola.
The number of digital subscriptions of the largest Baltic media group, AS Ekspress Grupp increased by 16% across all Baltic States in the 1st quarter of 2021 (74% year-over-year) and totalled 94 639 at the end of March. The number of digital subscriptions of AS Ekspress Meedia that publishes the news portal Delfi, newspapers Eesti Päevaleht, Maaleht, Eesti Ekspress and several popular magazines increased by 19% in the 1st quarter and 65% year-over-year, totalling 59 183.The number of digital subscriptions of AS Õhtuleht, 50% of which is owned by Ekspress Grupp, increased by 9% in the 1st quarter and 30% year-over-year, totalling 15 005.The market share of Ekspress Grupp in the digital subscriptions of all Estonian media outlets (according to the data by the Estonian Association of Media Enterprises) was 49% at the end of March.In Latvia, the number of digital subscriptions of Ekspress Grupp decreased by 5% in 1st quarter but doubled year-over-year, reaching 10 559 at the end of the 1st quarter. In Lithuania, the number of digital subscriptions totalled 9 892 at the end of the 1st quarter, increasing by 50% in a quarter and almost 6 times year-over-year. Both in Latvia and Lithuania, digital subscriptions are not as widespread as in Estonia with Ekspress Grupp launching them in the market in 2019. The Chairman of the Management Board of Ekspress Grupp Mari-Liis Rüütsalu: “The year 2021 is off to a good start in the market of digital subscriptions. Readers’ interest in high-quality content has increased, as evidenced by the increasing number of digital subscriptions. We have stayed ahead of our competitors while competition in digital subscriptions becomes more active. In the Baltics, Delfi holds a leadership position with its bundle package that provides access to a great number of media outlets run by Ekspress Meedia in Estonia. The decline in the number of subscriptions in Latvia in the 1st quarter is attributable to the restructuring of customer accounts under which the customers who previously had two different subscriptions were moved to a more extensive subscription bundle of Delfi + that includes several products. The number of digital subscriptions in Lithuania increased by 50% as compared to the previous quarter and Lithuania continues to be a market showing faster growth. Ekspress Grupp has set the growth of digital subscriptions as one of its most important goals, as it provides the Group's media outlets with a differentiated and increasingly stronger digital revenue base.” Detailed overview of digital subscriptions 31.03.202131.12.2020change31.03.2020changeAS Ekspress Meedia59 18349 69619%35 93665%AS Õhtuleht Kirjastus15 00513 8209%11 50630%Delfi AS (Latvia)10 55911 143-5%5 271100%Delfi UAB (Lithuania)9 8926 59550%1 565532%Total Ekspress Grupp 94 63981 25416%54 27874%Total market (Estonia)149 980126 60118%91 86563% Signe KukinCFO of the GroupAS Ekspress Grupp Telephone: +372 669 8381E-mail address: signe.kukin@egrupp.ee AS Ekspress Grupp is the leading media group in the Baltic States whose key activities include web media content production, publishing of newspapers and magazines and provision of printing services in Estonia, Latvia and Lithuania. Ekspress Grupp that launched its operations in 1989 employs almost 1600 people, owns leading web media portals in the Baltic States and publishes the most popular daily and weekly newspapers as well as the majority of the most popular magazines in Estonia.
GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK), Parkway Laboratories and the Diagnostics Development (DxD) Hub announced their collaboration to provide the cPass™ SARS-CoV-2 neutralizing antibody test in Singapore through Parkway's panel of specialist and GP clinics.
Cosmo Pharmaceuticals NV (SIX: COPN) today announced the FDA approval of GI Genius™ intelligent endoscopy system, its revolutionary device for lesion detection during colonoscopy.
REGEN-COV rapidly protected household contacts from exposure to SARS-CoV-2 at home, with 72% protection against symptomatic infections in the first week, and 93% in subsequent weeks
Among individuals who still experienced symptomatic infections, those who received casirivimab and imdevimab were able to clear the virus faster and had much shorter symptom durationIn a cohort of recently-infected asymptomatic patients, casirivimab and imdevimab reduced the overall risk of progressing to symptomatic COVID-19 by 31%Detailed results will be shared with regulatory authorities including the EMA and the FDA Basel, 12 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive results from the phase III REGN-COV 2069 trial assessing the ability of the investigational antibody cocktail casirivimab and imdevimab to reduce the risk and burden of COVID-19 infection among household contacts of SARS-CoV-2 infected individuals. The trial, which was jointly run with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), met its primary and key secondary endpoints. It showed that the subcutaneous administration of casirivimab and imdevimab reduced the risk of symptomatic infections by 81% in those who were not infected when they entered the trial. In addition, individuals treated with casirivimab and imdevimab who still experienced a symptomatic infection resolved their symptoms on average within one week, compared to three weeks with placebo. No new or serious safety signals were observed. “Today’s data confirm the potential dual value of casirivimab and imdevimab to reduce household COVID-19 infections and to decrease the disease burden in those who do become infected, when given as a subcutaneous option,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “Although vaccinations are increasing globally, there remains a critical unmet need worldwide to prevent infections and provide immediate protection from COVID-19 between close contacts. This is why we are excited to bring this data to health authorities with the goal of making the combination available to more people as soon as possible.” The phase III, double-blind, placebo-controlled trial assessed the effect of casirivimab and imdevimab on individuals without SARS-CoV-2 antibodies or any COVID-19 symptoms, who lived in the same household as an individual who tested positive to SARS-CoV-2 within the prior four days. It included 1,505 people who were not infected with SARS-CoV-2 at baseline and received either one dose of casirivimab with imdevimab (1,200 mg) or placebo, administered as subcutaneous injections. In addition, the multi-part study evaluated the antibody cocktail in a cohort of 204 recently infected asymptomatic patients randomised to receive either one dose of casirivimab and imdevimab (1,200 mg subcutaneous administration) or placebo. In this cohort, casirivimab and imdevimab reduced the overall risk of progressing to symptomatic COVID-19 by 31%. Detailed results from the trial will be shared with regulatory authorities as soon as possible. Regeneron will share new data with the United States (U.S.) Food and Drug Administration (FDA) and Roche and Regeneron will continue to work with the European Medicines Agency (EMA) and other health authorities across the globe. The antibody cocktail continues to be evaluated in clinical trials in multiple settings for COVID-19: in non-hospitalised and certain hospitalised patients, including the open-label RECOVERY trial of hospitalised patients in the UK. As of April 2021, more than 25,000 people have participated in clinical trials involving casirivimab and imdevimab. In these exceptional times, Roche stands together with society, governments, healthcare providers and all those working to overcome the pandemic. Table 1: Key results from phase III prevention cohort in uninfected individuals* Casirivimab and imdevimab(1,200 mg subcutaneous dose)Placebon=753n=752Proportion of subjects with symptomatic SARS-CoV-2 infections through day 29 (primary endpoint)Risk reduction81%(p<0.0001)# of patients with events11 (1.5%)59 (7.8%)Symptoms and viral loadTotal weeks with symptomsReduction93%(p<0.0001)Total # of weeks (cumulative for all individuals in each arm)13188# of weeks with symptoms (mean) in symptomatic individuals1.23.2Total weeks with high viral load (>104 copies/mL)Reduction90%(p<0.0001)Total # of weeks (cumulative for all individuals in each arm)14136# of weeks with high viral load (mean) in qPCR positive subjects0.41.3 *Individuals without any COVID-19 symptoms who lived in the same household as an individual who tested positive to SARS-CoV-2 within the prior four days. Based on the seronegative modified Full Analysis Set population, which includes all randomized subjects without evidence of current or prior SARS-CoV-2 infection (i.e., a negative RT-qPCR test and a negative antibody test) at randomization. Adverse events (AEs) occurred in 20% (n=265 out of 1,311) of REGEN-COV participants and 29% (n=379 out of 1,306) of placebo participants, and serious AEs occurred in 1% (n=10) of REGEN-COV participants and 1% (n=15) of placebo participants. There were 0 REGEN-COV participants and 4 placebo participants who were either hospitalized or visited the emergency room because of COVID-19 during the 29-day efficacy assessment period. Injection site reactions, all of which were grades 1-2, occurred in 4% (n=55) of REGEN-COV participants and 2% (n=19) of placebo participants. No individuals from either group withdrew from the trial due to AEs, and none of the deaths in the trial (2 REGEN-COV, 2 placebo) were attributed to COVID-19 or study drug. Table 2: Key results from phase III treatment cohort in asymptomatic infected individuals Casirivimab and imdevimab(single 1,200 mg dose)Placebon=100n=104Proportion of subjects with symptomatic SARS-CoV-2 infections through day 29 (primary endpoint)Risk reduction31%(p=0.0380)# of patients with events (cumulative for all individuals in each arm)29 (29%)44 (42%)Symptoms, viral load and COVID-19 related eventsTotal weeks with symptomsReduction45%(p=0.0273)Total # of weeks (cumulative for all individuals in each arm)90170Total weeks with high viral load (>104 copies/mL)Reduction40%(p=0.001)Total # of weeks4882 Based on the seronegative modified Full Analysis Set population, which includes all randomized asymptomatic patients who were SARS-CoV-2 positive but had no evidence of prior infection (i.e., a positive RT-qPCR test and a negative antibody test) at randomization Adverse events (AEs) occurred in 34% (n=52 out of 155) of REGEN-COV patients and 48% (n=75 out of 156) of placebo patients, and serious AEs occurred in 0% (n=0) of REGEN-COV patients and 3% (n=4) of placebo patients. Injection site reactions, all of which were grades 1-2, occurred in 4% (n=6) of REGEN-COV patients and 1% (n=1) of placebo patients. No patients from either group withdrew from the trial due to AEs, and there were no deaths. About REGN-COV 2069 REGN-COV 2069 is a phase III, randomised, double-blind, placebo-controlled multi-part study assessing the efficacy and safety of casirivimab and imdevimab in preventing symptomatic infection in household contacts of individuals infected with COVID-19. In January 2021, initial data from the trial showed that there was a reduction in overall infections seen with casirivimab and imdevimab within the first week, with approximately 50% lower overall rates of infection (symptomatic and asymptomatic) and 100% prevention of symptomatic infections. Casirivimab and imdevimab showed efficacy when administered via a low-dose (1,200 mg) subcutaneous route. In the safety assessment of these patients, adverse events occurred more frequently in participants on placebo during the efficacy analysis period (12% in the casirivimab and imdevimab group and 18% in the placebo group) and during the follow-up period (11% in the casirivimab and imdevimab group and 20% in the placebo group). About casirivimab and imdevimab Casirivimab and imdevimab is a cocktail of two monoclonal antibodies (also known as REGN10933 and REGN10987, respectively) and was designed by Regeneron scientists to block infectivity of SARS-CoV-2, the virus that causes COVID-19. They evaluated thousands of fully-human antibodies produced by the company's proprietary VelocImmune® mice, which have been genetically modified to have a human immune system, as well as antibodies identified from humans who have recovered from COVID-19. The two potent, virus-neutralising antibodies casirivimab and imdevimab are believed to bind non-competitively to the critical receptor binding domain of the virus's spike protein, which is hypothesised to diminish the ability of mutant viruses to escape treatment and to protect against spike variants that may arise in the human population, as detailed in Science publications. The cocktail of casirivimab and imdevimab has not been granted a marketing authorisation by any health authority. In November 2020, the antibody cocktail was authorised by the United States (U.S.) Food and Drug Administration (FDA) under an Emergency Use Authorization (EUA) for the treatment of mild to moderate COVID-19 in adults and paediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalisation. The US EUA is temporary and does not take the place of the formal biologics license application (BLA) submission, review and approval process. In February 2021, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a scientific opinion under Article 5(3) of Regulation 726/2004 supporting the use of casirivimab and imdevimab as a treatment option for patients with confirmed COVID-19 who do not require oxygen supplementation and who are at high risk of progressing to severe COVID-19. The scientific opinion can be considered by EU member states when making decisions on the use of medicines at a national level before a formal authorisation is issued. The review under Article 5(3) was separate, but ran in parallel to the rolling review of casirivimab and imdevimab, which is currently ongoing by the EMA. Casirivimab and imdevimab’s development, manufacturing and clinical trials have been funded in part by the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the US Department of Health and Human Services under OT number: HHSO100201700020C. About U.S. FDA EUA status Casirivimab and imdevimab have not been Food and Drug Administration (FDA) cleared or approved in the United States (US). It has been authorised by the FDA under an Emergency Use Authorization (EUA) during the current public health emergency for the treatment of mild to moderate COVID-19 in adults and paediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalisation. Please see the Fact Sheet for Healthcare Providers for more information, including important safety information. The cocktail is only authorised for the duration of the declaration that circumstances exist justifying the authorisation of the emergency use under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb3(b)(1), unless the declaration is terminated or authorisation revoked sooner. About Roche’s response to the COVID-19 pandemic As a leading healthcare company we are doing all we can to support countries in their fight against COVID-19 and minimising its impact. We have developed a growing number of diagnostic solutions that help to detect and diagnose the infection, as well as providing digital support to healthcare systems. We also continue to identify, develop and support potential therapies which can play a role in treating the disease. The impact of COVID-19 goes beyond those who contract it. That is why we are working with healthcare providers, laboratories, authorities and organisations to help make sure patients continue to receive the tests, treatment and care they need during these challenging times. Building on a longstanding tradition of partnerships, we are working together with governments and others to make healthcare stronger and more sustainable in the future. Reliable, high-quality testing is essential to help healthcare systems overcome this pandemic and Roche has so far launched 16 diagnostics solutions to help minimise the impact of COVID-19. As soon as the novel SARS-CoV-2 virus was sequenced in early 2020, we got to work. On 13 March 2020 we became the first company to receive U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for a high-volume molecular test to detect the virus. Since then, we have continued to add a range of diagnostics solutions to our global portfolio to help in the fight against COVID-19. In addition to the gold standard PCR test, we have developed antigen tests to help diagnose the virus in settings where there is limited molecular laboratory infrastructure, rapid antigen where the virus can be detected on the spot, tests that can test for both flu and COVID-19 at the same time, both high throughput and at the point of care, and tests that can detect virus antibodies that can help monitor the spread of the virus and can also support in vaccine development. On 16 March 2021 the SARS-CoV-2 variant test was launched, designed to detect key spike mutations. Aside from these tests we have also looked at how we can support care for patients who have COVID-19, receiving an FDA EUA for the Elecsys® IL-6 test to assist in identifying severe inflammatory response in patients with confirmed COVID-19, as well as launching Roche v-TAC, a digital algorithm that could help simplify the screening, diagnosis and monitoring of respiratory-compromised patients with COVID-19. Roche is working closely with governments and health authorities around the world, and has significantly increased production to support availability of tests globally. Roche is actively involved in understanding the potential of the existing portfolio and is researching options for the future. In 2020, Roche entered into a number of new partnerships, including with Gilead, Regeneron and Atea, to develop, manufacture and distribute molecules that can potentially both treat and prevent COVID-19. In October, Roche announced a partnership with Atea Pharmaceuticals to jointly develop the investigational compound AT-527. If approved, Atea will distribute AT-527 in the United States (US) and Roche will be responsible for global manufacturing and distribution outside the US. Atea’s compound has the potential to be the first oral antiviral to treat COVID-19 patients outside the hospital setting as well as in the hospital. Its anticipated formulation (pill) could allow for large-scale manufacturing and may help to facilitate access to a broad patient population. In November, our partner Regeneron received FDA EUA for casirivimab and imdevimab, its investigational antiviral antibody combination, for the treatment of recently diagnosed patients with mild to moderate COVID-19 who are at high risk of progressing to severe COVID-19 and/or hospitalisation. The antibody cocktail is currently being studied in two phase I-III adaptive clinical trials for the treatment of COVID-19 and in a phase III trial for the prevention of the disease. As part of the global partnership with Regeneron, we are committing a significant amount of manufacturing capacity and are working to expand supply of this antibody combination beyond the US to as many people as possible. In addition, we are exploring the potential of our investigational molecules and existing portfolio: For example, Roche has initiated three global phase III clinical trials investigating the safety and efficacy of Actemra/RoActemra in COVID-19 associated pneumonia (COVACTA, EMPACTA and REMDACTA). Following initial interactions with health authorities, Roche will continue to monitor the evolving clinical evidence for Actemra/RoActemra in this setting. About Roche Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI). The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com. All trademarks used or mentioned in this release are protected by law. Roche Group Media Relations Phone: +41 61 688 8888 / e-mail: media.relations@roche.com Dr. Nicolas Dunant Phone: +41 61 687 05 17 Patrick Barth Phone: +41 61 688 44 86Dr. Daniel Grotzky Phone: +41 61 688 31 10 Karsten Kleine Phone: +41 61 682 28 31Nina Mählitz Phone: +41 79 327 54 74 Nathalie Meetz Phone: +41 61 687 43 05Dr. Barbara von Schnurbein Phone: +41 61 687 89 67 Roche Investor Relations Dr. Karl Mahler Phone: +41 61 68-78503 e-mail: karl.mahler@roche.com Jon Kaspar Bayard Phone: +41 61 68-83894 e-mail: jon_kaspar.bayard@roche.comDr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.comDr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.comDr. Gerard Tobin Phone: +41 61 68-72942 e-mail: gerard.tobin@roche.com Investor Relations North America Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.comDr. Lisa Tuomi Phone: +1 650 467 8737 e-mail: tuomi.lisa@gene.com Attachment 12042021_MR_2069 phase III data of casivrimib and imdevimab_EN
Facility is the centerpiece of the cooperation between Clariant and TiangangEnhances ability to serve increasing demand from Chinese growth industriesContributes to Clariant’s growth ambitions in Chinese market Muttenz, April 12, 2021– Clariant, a focused, sustainable and innovative specialty chemical company, today announced the opening of a new world-class production facility for process and light stabilizers. The facility is jointly owned by Clariant and Beijing Tiangang Auxiliary Co., Ltd. (Tiangang), a privately owned producer and leading supplier of light stabilizers in China. Located within the Cangzhou National Coastal-Port Economy & Technology Development Zone in Cangzhou (Hebei Province), the facility forms the centerpiece of the partnership between both companies. It enables Clariant and Tiangang to continue their successful cooperation with an enhanced ability to fulfill the growing demand in China for high-end process and light stabilizers from local growth industries like automotive, textiles and coatings. “With this state-of-the-art facility, we enhance our ability to support Chinese customers with high-end stabilizers that fulfill their growing demands for sustainable solutions. It is through such expanded local production capacity, which is focused on fulfilling local needs and is supported by a strong local partner in Tiangang, that Clariant will keep outgrowing the local market,” said Conrad Keijzer, CEO of Clariant. China represents a key growth region for Clariant, and the company is committed to further enhancing its local production and R&D capabilities. In addition to this newly opened facility in Cangzhou, Clariant recently inaugurated its new One Clariant Campus in Shanghai, which includes a dedicated China Innovation Center. Furthermore, the company announced the construction of a new Catofin™ catalysts production facility in Jiaxing, Zhejiang Province, and considers initiating additional expansions in the near future. Combined with other components of its dedicated China strategy, these expansions will enable Clariant to grow its China sales (core business) beyond the current level of CHF 402 million in 2020, which represents approximately 10% of the Group’s continuing operations sales. Process and light stabilizers are types of additives used to reduce the degradation of plastics, in particular caused by exposure to the environmental conditions of light, heat and air. China is a key market for Clariant’s range of such stabilizers, which include the state-of-the-art Nylostab® S-EED® chemistry – invented by Clariant – a unique multifunctional hindered amine light stabilizer, or HALS – for polyamid. “As a leader in high-end additive solutions, we are very excited to extend our production footprint and step up local access to high-performing, sustainable solutions. Combining the strengths of both Clariant and Tiangang in a world-class production facility in China, close to our customers, makes perfect sense. It fastens our ability to support the specific and evolving challenges of our customers with sustainable and high-quality offerings,” said Francois Bleger, Global Head of Clariant’s Business Unit Additives. The joint venture between Clariant and Tiangang was established in September 2017 and combines the technology and production knowledge of both companies to provide even better process and light stabilizers for various growing industries in China. These industries seek to develop in accordance with China’s economic and climate-related goals and Clariant is able to provide advanced technologies and sustainable products needed to do so. Furthermore, as the drive for sustainability is becoming a truly global movement, Clariant is confident that its production facilities in China will help fulfil a worldwide growing demand for innovative and sustainable products. Mr. Gang Liu, Executive Director of Tiangang announced: "The official opening of the facility marks a great milestone in the cooperation between both companies. Built on the expertise of both partners, the production facility will now serve the growing demand for high-end additives solutions in Asia with world-class quality products and exceptional service.” More information about the opening, as well as Clariant’s participation in the Chinaplas trade show can be found via https://www.clariant.com/en/Corporate/Events/2021/04/2021-Chinaplas-Clariant-Additives-JV-Cangzhou-Opening-Ceremony Corporate Media Relations Investor Relations Jochen Dubiel Phone +41 61 469 63 63jochen.dubiel@clariant.com Andreas Schwarzwälder Phone +41 61 469 63 73andreas.schwarzwaelder@clariant.com Claudia Kemansky Phone +41 61 469 63 63claudia.kamensky@clariant.com Maria Ivek Phone +41 61 469 63 73maria.ivek@clariant.com Thijs Bouwens Phone +41 61 469 63 63thijs.bouwens@clariant.com Alexander Kamb Phone +41 61 469 63 73alexander.kamb@clariant.com Follow us on Twitter, Facebook, LinkedIn, Instagram. This media release contains certain statements that are neither reported financial results nor other historical information. This document also includes forward-looking statements. Because these forward-looking statements are subject to risks and uncertainties, actual future results may differ materially from those expressed in or implied by the statements. Many of these risks and uncertainties relate to factors that are beyond Clariant’s ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behavior of other market participants, the actions of governmental regulators and other risk factors such as: the timing and strength of new product offerings; pricing strategies of competitors; the Company’s ability to continue to receive adequate products from its vendors on acceptable terms, or at all, and to continue to obtain sufficient financing to meet its liquidity needs; and changes in the political, social and regulatory framework in which the Company operates or in economic or technological trends or conditions, including currency fluctuations, inflation and consumer confidence, on a global, regional or national basis. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this document. Clariant does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date of these materials. www.clariant.com Clariant is a focused, sustainable and innovative specialty chemical company based in Muttenz, near Basel/Switzerland. On 31 December 2020, the company employed a total workforce of 13 235. In the financial year 2020, Clariant recorded sales of CHF 3.860 billion for its continuing businesses. The company reports in three business areas: Care Chemicals, Catalysis and Natural Resources. Clariant’s corporate strategy is based on five pillars: focus on innovation and R&D, add value with sustainability, reposition portfolio, intensify growth, and increase profitability. Attachments Clariant Media Release Additives facility opening in Cangzhou China 20210412 EN Clariant Media Release Additives facility opening in Cangzhou China 20210412 DE
Here’s what’s happening in the world of television for Monday, April 12. All times are Eastern.
The net asset value (NAV) of EfTEN Real Estate Fund III AS as of 31.03.2021 was 17.35 euros. The net asset value of the EPRA share (net book value excluding deferred income tax liability and fair value of interest rate derivatives) as of 31.03.2021 was 18.48 euros. Both NAV and EPRA NAV increased 0.9% during March. In March, EfTEN Real Estate Fund III AS earned a total of 961 thousand euros in consolidated sales revenue, which is at the same level as in February. The fund's EBITDA was 817 thousand euros in March, which is 18 thousand euros more than in February due to lower general expenses. In a situation of accelerated spread and increased restrictions on Covid-19, the fund's results in the first quarter of 2021 are better than expected. In Saules Miestas shopping center in Lithuania, rental income has decreased on average by 22% compared to the first quarter of the previous year due to temporary discounts, but the crisis did not have a significant effect on the rental income of other properties in the first quarter of 2021. At the same time, additional agreements have been concluded with some tenants to defer rent payments until May, which in turn will have a temporary negative effect on the fund's cash flows. In the first quarter of 2021, new lease agreements were signed in Ulonu and Laisves office buildings in Lithuania, which reduced the fund's vacancy rate to 0.8%, i.e. only 934 m2 of the fund’s portfolio’s total leasable area (124 thousand m2) is vacant as of 31.03.2021. In the first quarter of this year, EfTEN Real Estate Fund III AS has earned a total of 2.9 million euros in consolidated sales revenue,which is 15% more than in the first quarter of the previous year. The increase in sales revenue is related to new property investments last year, but also to a decrease in vacancies in Lithuanian office buildings. The negative impact of Covid-19 on the fund's rental income compared to the first quarter of the previous year is on average 150 thousand euros. Without temporary Covid-19 discounts, the fund's real estate portfolio would earn 8.3% higher sales revenue. The consolidated equity of EfTEN Real Estate Fund III AS was 73.278 million euros as of 31.03.2021 (31.12.2020: 71.483 million euros). Marilin HeinCFOPhone 655 9515E-mail: marilin.hein@eften.ee Attachment EREF_III_reports_monthly_03_2021
Unifiedpost Group (Euronext: UPG) (Unifiedpost), a leading European fintech company, is proud to announce the acquisition of Crossinx GmbH. The acquisition is a major step in the realisation of the group’s strategy. The solutions of both companies and their markets are highly complementary. By joining forces, the combined group can now offer full order-to-cash and procure-to-pay solutions to small businesses, medium-sized corporates and large enterprises. Unifiedpost now also gets access to the important German market, and even the full DACH region and Hungary. By bringing the businesses and solutions together, multiple avenues of additional value creation are unlocked. Unifiedpost therefore also raises the financial guidance it has given to the market.
Thousands of shoppers swear by GrandeLash and GrandeBrow, and I'm now one of them.
Yahoo Home